Summary It is the industry analysis specialist’s new report, “Dyslipidemia - Drug Pipeline Analysis and Market Forecasts to 2016"" is an essential source of information and analysis on the global dyslipidemia market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global dyslipidemia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global dyslipidemia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by its team of industry experts. Scope The scope of the report includes: - Annualized global dyslipidemia market revenue data from 2001 to 2009, forecast for seven years to 2016. - Geographies covered in this report are the US, the UK, Italy, Spain, Germany, France, and Japan. - Pipeline analysis data split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action include combination therapies, CETP inhibitors, MTP inhibitors, PPAR agonists, thyroid hormone receptor modulators, gene therapies, nicotinic acid receptor agonists, AMPK modulators, enzyme inhibitors, cholesterol absorption inhibitors, farsenyl X receptor agonists, prostacyclin release stimulators, CB1 receptor agonists, A1 adenosine receptor agonists and omega-3 fatty acid derivatives. - Analysis of the current and future market competition in the global dyslipidemia market. The key future market players covered are AstraZeneca PLC, Abbott Laboratories, Merck & Co., GenFit, Aegerion Pharmaceuticals, Inc., Amarin Corporation Plc, Pfizer Inc., and F. Hoffman-La Roche. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. - The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future dyslipidemia market. For more information, please visit : http://www.aarkstore.com/reports/Dyslipidemia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-37971.html Or email us at press@aarkstore.com or call +919272852585 Aarkstore Enterprise Tel : +912227453309 Mobile No: +919272852585 Email : contact@aarkstore.com Website : http://www.aarkstore.com Blog: http://blogs.aarkstore.com/ Follow us on twitter: http://twitter.com/aarkstoredotcom
Related Articles -
Dyslipidemia, Drug, Pipeline, Analysis, Market, Forecasts, Market, Research, Report, Business, Industry, Information, Automotive, Banking, Finance,
|